A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

NCT06840002 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: SHR-A1811
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Oxaliplatin for Injection
DRUG: Paclitaxel injection
DRUG: Doxorubicin hydrochloride liposome injection
DRUG: Adebrelimab Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.